



# Office of Continuing Education

Please fill out the form below **IN INK** to verify participation in this CE activity and fax to 713-500-0606. If requesting Nursing credit please also complete the attached Post Test Questions

**TOPIC:** Hematologic Malignancies Module I & Genitourinary Module II

**DATE:** September 23, 2008

**SPEAKER:** Nicholas DiBella, M.D. & William Berry, M.D.

**LOCATION:** Enduring Material

**OBJECTIVES:**

- Utilize recent research results to determine the optimal treatment options for patients with leukemia and myelodysplastic syndromes
- Apply the evidence-based data reviewed at this activity to the current management of patients with lymphoma and plasma cell disorders
- Incorporate the most-effective treatment options into management strategies for multiple myeloma patients based on data presented at this meeting
- Apply recent research outcomes toward the management of genitourinary cancer patients

**DISCLOSURE:**

Dr. DiBella has nothing to disclose. Dr. Berry is on the Speaker's Bureau for sanofi-aventis. He will be discussing investigational drugs including satraplatin, abiraterone acetate, MDV-3100, and everolimus, and unlabeled uses of thalidomide and bevacizumab.

**Accreditation:** This program has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Texas Medical Branch at Galveston and Oncology Today. The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CME** The University of Texas Medical Branch at Galveston designates this educational activity for a maximum of (1.5) *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**CNE** This program has been approved by the American Association of Critical Care Nurses (AACN) for 1 Contact Hour, Category A, File Number 2008 - (1213a).

**ACPE** The University of Houston College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education. Pharmacists documenting completion of the program "Hematologic Malignancy Updates and Updates in Genitourinary Cancers" (# 066-999-08-030-L01-P) by signing in, completing evaluations and a post-test exam will receive 1 contact hour (0.1 CEU) pharmacy continuing education credit, and will receive a statement of credit by mail within 3 weeks of UHCOP being notified of the completion date. Initial Release Date: October 10, 2008. Expiration Date: October 10, 2011.

### CREDIT CANNOT BE AWARDED UNLESS FORM IS COMPLETELY LEGIBLE

<b>First Name</b>	<b>MI</b>	<b>Last Name</b>	<b>Title</b>
<b>Address:</b> _____			
<b>City:</b> _____	<b>State:</b> _____	<b>Zip:</b> _____	
<b>Phone:</b> _____	<b>Fax:</b> _____	<b>Email:</b> _____	

### PLEASE COMPLETE EVALUATION FORM BEFORE RETURNING

- Make solid marks that fill the response completely.
  - Make no stray marks on this form.
- Scale: 1= Strongly Disagree    2= Disagree    3= Agree    4= Strongly Agree**

①	②	③	④	<b>The content of this presentation is applicable to my professional development.</b>
①	②	③	④	<b>The course objectives were met.</b>
①	②	③	④	<b>The presentation was clear and understandable.</b>
①	②	③	④	<b>The program was free of commercial bias and presented in an objective manner.</b>
①	②	③	④	<b>The presentation was scientifically based and accurate.</b>
①	②	③	④	<b>As a result of this course, my professional effectiveness will increase.</b>

Disagree ←————→ Agree

**Comments for strengths and improvements:** \_\_\_\_\_

6431 Fannin St. JLL 435 | Houston, TX 77030  
PHONE (713) 500-5249 | FAX (713) 500-0606 | <http://www.utcme.net>



ACPE The University of Houston College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education



Name \_\_\_\_\_

Please complete the following questions if requesting nursing or pharmacy credit.

## Hematologic Malignancies Module I

1. For patients with Philadelphia chromosome positive ALL, TKIs should be incorporated into remission induction and maintenance therapy.
  - a. True
  - b. False

## Genitourinary Module II

2. According to recent trial data, which of the following is the reference standard for first line therapy for metastatic renal cell carcinoma?
  - a. Interferon – alpha
  - b. Sunitinib

Please fax completed forms to 713-500-0606